|Bid||8,338.00 x 0|
|Ask||8,341.00 x 0|
|Day's range||8,337.00 - 8,409.00|
|52-week range||6,499.80 - 10,120.00|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||38.84|
|Earnings date||29 Jul 2021|
|Forward dividend & yield||2.07 (2.48%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||78.83|
The Institute for Antiracism in Medicine Co-Founder & The University of Illinois College of Medicine Assistant Professor of Clinical & Family Medicine Dr. Brittani James joins Yahoo Finance Live to discuss the latest updates amid the COVID-19 pandemic.
An experimental antibody treatment designed to stop people developing Covid-19 after being exposed to the virus has failed clinical trials, dealing a blow to Britain's hopes of developing a new weapon to fight coronavirus. Anglo-Swedish drugmaker AstraZeneca gave an antibody drug to unvaccinated adults who had been exposed to Covid-19 within the past eight days. Antibody treatments are meant to work by pumping patients with antibodies to boost their immune system and stop them from developing a
AZD7442 failed to meet the main goal of stopping people developing symptomatic COVID-19 but did offer some hope that it could help people who had not yet come into contact with the virus.